Journal article
Treatment of metastatic carcinoid tumors with radiolabeled biologic molecules
Journal of the National Comprehensive Cancer Network, Vol.7(7), pp.760-764
07/2009
DOI: 10.6004/jnccn.2009.0052
PMID: 19635228
Abstract
Treatment options in advanced-stage neuroendocrine tumors are limited. A promising new category of therapy was recently introduced for these tumors in which radioactive atoms are attached to molecules that target and bind to neuroendocrine cancer cells. 90Yttrium-DOTA-Phe1-Tyr3-octreotide and radioactive drugs which targets cells by binding to somatostatin receptors. 131Iodine-metaiodobenzylguanidine also targets neuroendocrine tumors using the amine transporter system. Both agents, along with the somatostatin analogue 177Lutetium-DOTATATE, have shown objective response rates in approximately 30% of patients with progressive metastatic disease. Symptomatic improvement is observed in most patients receiving these drugs and evidence of survival benefit is also mounting. Serious side effects are uncommon.
Details
- Title: Subtitle
- Treatment of metastatic carcinoid tumors with radiolabeled biologic molecules
- Creators
- David Bushnell - University of Iowa Hospitals and Clinics
- Resource Type
- Journal article
- Publication Details
- Journal of the National Comprehensive Cancer Network, Vol.7(7), pp.760-764
- DOI
- 10.6004/jnccn.2009.0052
- PMID
- 19635228
- ISSN
- 1540-1405
- eISSN
- 1540-1413
- Language
- English
- Date published
- 07/2009
- Academic Unit
- Radiology
- Record Identifier
- 9984318703502771
Metrics
4 Record Views